Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

PEP4LEP 2.0 - Chemoprohylaxis for leprosy: comparing the effectiveness and feasibility of a community-based intervention to a health centre-based intervention in Ethiopia, Mozambique, and Tanzania.

Project description

Protecting those at risk of developing leprosy in Ethiopia, Tanzania and Mozambique

Leprosy is an infectious disease that can cause impairments, making early detection, treatment, and prevention essential to reduce transmission and ensuing complications. Ethiopia, Tanzania, and Mozambique are known as high-endemic areas for leprosy. The World Health Organization recommends single-dose rifampicin post-exposure prophylaxis (SDR-PEP) for contacts of leprosy patients. The EU-funded PEP4LEP 2.0 project aims to identify the most effective integrated approach for screening individuals for leprosy, neglected infectious skin diseases, and common skin diseases to assess eligibility for SDR-PEP administration. The study compares two approaches: a community-based skin camp and a health centre-based screening. It also collects additional data to assess the impact of the pandemic on these interventions, the cost-effectiveness and acceptability of both interventions, and the capacity of health workers.

Objective

BACKGROUND - Leprosy is a significant public health problem. Early detection, treatment, and prevention are crucial to reduce transmission and disabilities. The World Health Organization (WHO) recommends single-dose rifampicin post-exposure prophylaxis (SDR-PEP) for screened contacts of leprosy patients. The PEP4LEP 2.0 study builds upon the EDCTP2-PEP4LEP project to identify the most effective intervention to screen individuals for leprosy, other skin neglected infectious diseases (skinNIDs) and common skin diseases, and to provide SDR-PEP. The study takes place in leprosy high-endemic areas in Ethiopia, Tanzania and Mozambique. It determines which intervention has most effect on leprosy case finding and detection delay. However, the COVID-19 pandemic hampered the initial PEP4LEP study through delayed interventions and medication shortages, affecting the main outcome indicator: case detection delay.
METHODS - PEP4LEP 2.0 is a two-arm, cluster-randomized implementation trial to compare two interventions: 1) a community-based skin camp intervention, screening 100 leprosy patient's community contacts for leprosy and other skin diseases, and administering SDR-PEP; and 2) a health centre-based screening intervention, inviting leprosy patients’ household contacts to health centres for screening and SDR-PEP. To ensure a scientific sound analysis, PEP4LEP 2.0 collects additional data, increasing the sample size by 25%, to understand the pandemic's effects and enable analysis with and without COVID-19 influences. Skin camp organization, skinNID distribution, health staff capacity and acceptability will also be studied. Results will be modelled to assess the long-term impact related to costs.
IMPACT - PEP4LEP 2.0 results will reflect scientific, societal and economic impact towards reduced leprosy transmission. They will be disseminated to all stakeholders: scientists, policymakers, WHO, health staff, affected communities, NGOs and the general public in the EU and Africa.

Programme(s)

Coordinator

NEDERLANDSE STICHTING VOOR LEPRABESTRIJDING
Net EU contribution
€ 429 732,50
Address
WIBAUSTRAAT 137K
1097 DN AMSTERDAM
Netherlands

See on map

Region
West-Nederland Noord-Holland Groot-Amsterdam
Activity type
Other
Links
Total cost
€ 429 732,50

Participants (5)